Related Experiment Video
Updated: Jul 7, 2026

Intracameral Injection in Rats with Low Risk of Adverse Effects
Published on: May 31, 2024
Intraocular avastin (bevacizumab) for neovascularisation of the iris and neovascular glaucoma
Jacob Y C Cheng1, Doric W K Wong, Chong Lye Ang
1Vitreoretina Department, Singapore National Eye Centre, Singapore. jacob.cheng@singhealth.com.sg
Introduction:
The aim of this study was to determine the effectiveness of intraocular injections of bevacizumab for neovascularisation of the iris and neovascular glaucoma.
Clinical Picture:
Three patients with neovascularisation of the iris due to various causes were recruited.
Treatment:
Patients were treated with intraocular bevacizumab.
Outcome:
Neovascularisation of the iris was noted to have completely regressed as early as 3 days after the injection and in all the patients (100%) within 8 days after injection. They were followed up for at least 1 month with no clinical evidence of recurrence. Visual acuity remained stable or improved, and the intraocular pressure was controlled in all the 3 patients' eyes. Vitreous haemorrhage also cleared. No signs of inflammation or complications were observed.
Conclusion:
Intraocular injection of bevacizumab is effective and safe for patients with neovascularisation of the iris and neovascular glaucoma with or without vitreous haemorrhage.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Glaucoma: Overview
